RT Journal Article
SR Electronic
T1 Quantifying the impact of cascade inequalities: a modelling study on the prevention impacts of antiretroviral therapy scale-up in Eswatini
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.16.24302584
DO 10.1101/2024.02.16.24302584
A1 Knight, Jesse
A1 Ma, Huiting
A1 Sithole, Bheki
A1 Khumalo, Lungile
A1 Wang, Linwei
A1 Schwartz, Sheree
A1 Muzart, Laura
A1 Matse, Sindy
A1 Mnisi, Zandile
A1 Kaul, Rupert
A1 Escobar, Michael
A1 Baral, Stefan
A1 Mishra, Sharmistha
YR 2024
UL http://medrxiv.org/content/early/2024/05/13/2024.02.16.24302584.abstract
AB Background Inequalities in the antiretroviral therapy (ART) cascade across subpopulations remain an ongoing challenge in the global HIV response. Eswatini achieved the UNAIDS 95-95-95 targets by 2020, with differentiated programs to minimize inequalities across subpopulations, including for female sex workers (FSW) and their clients. We sought to estimate additional HIV infections expected in Eswatini if cascade scale-up had not been equal, and under which epidemic conditions these inequalities could have the largest influence.Methods Drawing on population-level and FSW-specific surveys in Eswatini, we developed a compartmental model of heterosexual HIV transmission which included eight subpopulations and four sexual partnership types. We calibrated the model to stratified HIV prevalence, incidence, and ART cascade data. Taking observed cascade scale-up in Eswatini as the basecase — reaching 95-95-95 in the overall population by 2020 — we defined four counterfactual scenarios in which the population overall reached 80-80-90 by 2020, but where FSW, clients, both, or neither were disproportionately left behind, reaching only 60-40-80. We quantified relative additional cumulative HIV infections by 2030 in counterfactual vs base-case scenarios. We further estimated linear effects of viral suppression gap among FSW and clients on additional infections by 2030, plus effect modification by FSW/client population sizes, rates of turnover, and HIV prevalence ratios.Results Compared with the base-case scenario, leaving behind neither FSW nor their clients led to the fewest additional infections by 2030: median (95% credible interval) 14.9 (10.4, 18.4) % vs 26.3 (19.7, 33.0) % if both were left behind — a 73 (40, 149) % increase. The effect of lower cascade on additional infections was larger for clients vs FSW, and both effects increased with population size and relative HIV incidence.Conclusions Inequalities in the ART cascade across subpopulations can undermine the anticipated prevention impacts of cascade scale-up. As Eswatini has shown, addressing inequalities in the ART cascade, particularly those that intersect with high transmission risk, could maximize incidence reductions from cascade scale-up.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by: the Natural Sciences and Engineering Research Council of Canada (CGS-D); the Ontario Ministry of Colleges and Universities (QEII-GSST); the Canadian Institutes of Health Research (FN-13455); the National Institute of Allergy and Infectious Diseases (R01AI170249). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We used only published aggregate data, except for individual-level data from two female sex worker surveys, which were accessed under approval fromthe Scientific and Ethics Committee of Swaziland (Eswatini) Ministry of Health (MH/599B), and the Institutional Review Board of the Johns Hopkins Bloomberg School of Public Health (3508).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll code and selected results are available on GitHub. https://github.com/mishra-lab/hiv-model-eswatini